
Article 1 
The Annex to Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.
Article 2 
This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 8 December 2020.
For the Commission
The President
Ursula VON DER LEYEN
ANNEX

The Annex to Regulation (EU) No 540/2011 is amended as follows:
Part A is amended as follows:

((1)) In the sixth column, expiration of approval, of entry 311, quinmerac, the date 30 April 2024 is replaced by31 July 2024.
((2)) In the sixth column, expiration of approval, of entry 314, zinc phosphide, the date 30 April 2024 is replaced by31 July 2024.
((3)) In the sixth column, expiration of approval, of entry 317, 6-benzyladenine, the date 31 May 2024 is replaced by 31 August 2024.
((4)) In the sixth column, expiration of approval, of entry 323, dodine, the date 31 May 2024 is replaced by 31 August 2024.
((5)) In the sixth column, expiration of approval, of entry 328, tau-fluvalinate, the date 31 May 2024 is replaced by 31 August 2024.
((6)) In the sixth column, expiration of approval, of entry 330, bupirimate, the date 31 May 2024 is replaced by 31 August 2024.
((7)) In the sixth column, expiration of approval, of entry 333, 1-decanol, the date 31 May 2024 is replaced by 31 August 2024.
((8)) In the sixth column, expiration of approval, of entry 334, isoxaben, the date 31 May 2024 is replaced by 31 August 2024.
((9)) In the sixth column, expiration of approval, of entry 335, fluometuron, the date 31 May 2024 is replaced by 31 August 2024.
((10)) In the sixth column, expiration of approval, of entry 341, sintofen, the date 31 May 2024 is replaced by 31 August 2024.
((11)) In the sixth column, expiration of approval, of entry 343, azadirachtin, the date 31 May 2024 is replaced by 31 August 2024.
((12)) In the sixth column, expiration of approval, of entry 345, lime sulphur, the date 31 May 2024 is replaced by 31 August 2024.
((13)) In the sixth column, expiration of approval, of entry 346, aluminium sulfate, the date 31 May 2024 is replaced by 31 August 2024.
((14)) In the sixth column, expiration of approval, of entry 350, tebufenozide, the date 31 May 2024 is replaced by 31 August 2024.
((15)) In the sixth column, expiration of approval, of entry 351, dithianon, the date 31 May 2024 is replaced by 31 August 2024.
((16)) In the sixth column, expiration of approval, of entry 352, hexythiazox, the date 31 May 2024 is replaced by 31 August 2024.
((17)) In the sixth column, expiration of approval, of entry 353, flutriafol, the date 31 May 2024 is replaced by 31 August 2024.
Part B is amended as follows:

((1)) In the sixth column, expiration of approval, of entry 24, fluxapyroxad, the date 31 December 2022 is replaced by 31 May 2025.
((2)) In the sixth column, expiration of approval, of entry 26, Adoxophyes orana granulovirus, the date 31 January 2023 is replaced by 31 January 2024.
((3)) In the sixth column, expiration of approval, of entry 37, Candida oleophila strain O, the date 30 September 2023 is replaced by 31 December 2024.
((4)) In the sixth column, expiration of approval, of entry 39, Paecilomyces fumosoroseus strain FE 9901, the date 30 September 2023 is replaced by 31 December 2024.
((5)) In the sixth column, expiration of approval, of entry 40, potassium phosphonates, the date 30 September 2023 is replaced by 31 January 2026.
((6)) In the sixth column, expiration of approval, of entry 43, bixafen, the date 30 September 2023 is replaced by 31 May 2025.
((7)) In the sixth column, expiration of approval, of entry 48, sedaxane, the date 31 January 2024 is replaced by 31 May 2025.
((8)) In the sixth column, expiration of approval, of entry 49, emamectin, the date 30 April 2024 is replaced by 30 November 2024.
((9)) In the sixth column, expiration of approval, of entry 50, Pseudomonas sp. strain DSMZ 13134, the date 31 January 2024 is replaced by 31 January 2025.
((10)) In the sixth column, expiration of approval, of entry 52,Aureobasidium pullulans (strains DSM 14940 and DSM 14941), the date 31 January 2024 is replaced by 31 January 2025.
((11)) In the sixth column, expiration of approval, of entry 53, pyriofenone, the date 31 January 2024 is replaced by 31 January 2025.
((12)) In the sixth column, expiration of approval, of entry 54, disodium phosphonate, the date 31 January 2024 is replaced by 31 January 2026.
((13)) In the sixth column, expiration of approval, of entry 55, penflufen, the date 31 January 2024 is replaced by 31 May 2025.
((14)) In the sixth column, expiration of approval, of entry 56, orange oil, the date 30 April 2024 is replaced by 31 July 2024.
((15)) In the sixth column, expiration of approval, of entry 57, penthiopyrad, the date 30 April 2024 is replaced by 31 May 2025.
((16)) In the sixth column, expiration of approval, of entry 58, benalaxyl-M, the date 30 April 2024 is replaced by 30 April 2025.
((17)) In the sixth column, expiration of approval, of entry 59, tembotrione, the date 30 April 2024 is replaced by 31 July 2024.
((18)) In the sixth column, expiration of approval, of entry 60, spirotetramat, the date 30 April 2024 is replaced by 31 July 2024.
((19)) In the sixth column, expiration of approval, of entry 61, pyroxsulam, the date 30 April 2024 is replaced by 30 April 2025.
((20)) In the sixth column, expiration of approval, of entry 62, chlorantraniliprole, the date 30 April 2024 is replaced by 31 December 2024.
((21)) In the sixth column, expiration of approval, of entry 63, sodium silver thiosulfate, the date 30 April 2024 is replaced by 31 July 2024.
((22)) In the sixth column, expiration of approval, of entry 64, pyridalyl, the date 30 June 2024 is replaced by 30 June 2025.
((23)) In the sixth column, expiration of approval, of entry 68, 1,4-dimethylnaphthalene, the date 30 June 2024 is replaced by 30 June 2025.
((24)) In the sixth column, expiration of approval, of entry 69, amisulbrom, the date 30 June 2024 is replaced by 30 September 2024.
((25)) In the sixth column, expiration of approval, of entry 65, S-abscisic acid, the date 30 June 2024 is replaced by 30 September 2024.
((26)) In the sixth column, expiration of approval, of entry 66, L-ascorbic acid, the date 30 June 2024 is replaced by 30 September 2024.
((27)) In the sixth column, expiration of approval, of entry 67, spinetoram, the date 30 June 2024 is replaced by 30 September 2024.
((28)) In the sixth column, expiration of approval, of entry 70, valifenalate, the date 30 June 2024 is replaced by 30 September 2024.
((29)) In the sixth column, expiration of approval, of entry 71, thiencarbazone, the date 30 June 2024 is replaced by 30 September 2024.
((30)) In the sixth column, expiration of approval, of entry 72, acequinocyl, the date 31 August 2024 is replaced by 30 November 2024.
((31)) In the sixth column, expiration of approval, of entry 73, ipconazole, the date 31 August 2024 is replaced by 30 November 2024.
((32)) In the sixth column, expiration of approval, of entry 74, flubendiamide, the date 31 August 2024 is replaced by 30 November 2024.
((33)) In the sixth column, expiration of approval, of entry 75, Bacillus pumilus QST 2808, the date 31 August 2024 is replaced by 31 August 2025.
((34)) In the sixth column, expiration of approval, of entry 79, Streptomyces lydicus strain WYEC 108, the date 31 December 2024 is replaced by 31 December 2025.
Part E is amended as follows:

((1)) In the sixth column, expiration of approval, of entry 6, prosulfuron, the date 30 April 2024 is replaced by 31 July 2024.
((2)) In the sixth column, expiration of approval, of entry 7, pendimethalin, the date 31 August 2024 is replaced by 30 November 2024.
((3)) In the sixth column, expiration of approval, of entry 8, imazamox, the date 31 October 2024 is replaced by 31 January 2025.
